

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



## **UNITED GENE HIGH-TECH GROUP LIMITED**

**聯合基因科技集團有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

### **EXTENSION OF LONG STOP DATES IN RELATION TO THE PROPOSED VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION**

Reference is made to the announcement of United Gene High-Tech Group Limited (the “**Company**”) dated 15 May 2013 (the “**Announcement**”) in relation to, among others, the Transactions (as defined in the Announcement) and the announcements of the Company dated 2 August 2013 and 23 August 2013 in relation to the delay in despatch of the Circular (the “**Delay Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement and the Delay Announcements unless defined otherwise.

#### **THE SECOND SUPPLEMENTAL AGREEMENT**

As disclosed in the Announcement, Completion I is conditional upon, among other things, the fulfillment of certain conditions precedent on or before Long Stop Date I, being 30 August 2013 or such other date as the Vendors and the Company may agree in writing.

Further, as disclosed in the Announcement, Completion II is conditional upon, among other things, the fulfillment of certain conditions precedent on or before Long Stop Date II, being 30 October 2013 or such other date as the Vendor A and the Company may agree in writing.

As additional time is required for the fulfillment of the said conditions precedent, on 30 August 2013 (after trading hours), the Vendors and the Company entered into the second supplemental agreement to the S&P Agreement (as amended and supplemented by a supplemental agreement dated 7 May 2013 (the “**First Supplemental Agreement**”)), pursuant to which (i) the Vendors and the Company agreed to extend Long Stop Date I to 30 November 2013 or such other date as the Vendors and the Company may agree in writing; and (ii) Vendor A and the Company agreed to extend Long Stop Date II to 31 January 2014 or such other date as Vendor A and the Company may agree in writing.

Save and except for the above, all other terms and conditions of the S&P Agreement and the First Supplemental Agreement shall remain unchanged and continue in full force and effect.

**Completion of the Transactions is subject to fulfillment of the conditions precedent as set out in the sections headed “Transaction I – Conditions precedent” and “Transaction II – Conditions precedent” in the Announcement. As the Transactions may or may not proceed, Shareholders and potential investors of the Company are advised to exercise caution when dealing in securities of the Company, and if they are in any doubt about their position, they should consult their professional advisers.**

By Order of the Board  
**United Gene High-Tech Group Limited**  
**Lee Nga Yan**  
*Executive Director*

Hong Kong, 30 August 2013

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).*